On this page
MOCS1
molybdenum cofactor synthesis 1
The MOCS1 gene provides instructions for creating two proteins, MOCS1A and MOCS1B, which are essential for the initial stages of molybdenum cofactor production within the body. MOCS1 is a gene critical for the biosynthesis of molybdenum cofactor, a molecule required for the function of several vital enzymes.
MOCS1 is located on the short (p) arm of chromosome 6, at band 6p21.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 6 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The MOCS1 gene, also known as molybdenum cofactor synthesis 1, is crucial for producing molybdenum cofactor (MoCo). MoCo is a small molecule containing molybdenum that is indispensable for the activity of several enzymes, including sulfite oxidase, aldehyde oxidase, and xanthine dehydrogenase [PMID:16538561]. These enzymes play important roles in metabolism, breaking down various substances and preventing the accumulation of potentially toxic compounds in the body.
Disruptions in MOCS1 function can lead to an inability to properly synthesise MoCo, resulting in molybdenum cofactor deficiency. This inherited metabolic disorder can have severe neurological consequences.
What the gene does
The MOCS1 gene directs the synthesis of two distinct proteins, MOCS1A and MOCS1B, both of which are involved in the initial steps of molybdenum cofactor biosynthesis. MOCS1A and MOCS1B perform the first reactions in the pathway that produces molybdenum cofactor [PMID:11932204]. While MOCS1A is a key enzyme in this process, the precise function of MOCS1B is not yet fully understood.
The molybdenum cofactor is subsequently incorporated into several enzymes that are vital for detoxification and normal metabolic processes. These enzymes include sulfite oxidase, aldehyde oxidase, xanthine dehydrogenase, and mitochondrial amidoxime reducing component (mARC). Without functional MOCS1 proteins, the body cannot produce sufficient molybdenum cofactor, leading to the impaired activity of these essential enzymes and the build-up of harmful metabolites.
Video: Genetics 101
Chromosome location
The MOCS1 gene is situated on chromosome 6 at position 6p21.2. This location refers to the short (p) arm of chromosome 6, specifically within region 21, band 2. The gene spans a significant segment of the chromosome and contains the genetic instructions necessary for synthesising the MOCS1 proteins.
Protein structure
The MOCS1 protein has a length of 636 amino acids and features several distinct functional regions. It includes a Molybdenum cofactor biosynthesis protein A region spanning amino acids 1-383, which contains a Radical SAM core domain from amino acids 64-277. An important region for catalytic activity is located at amino acids 384-385. The protein also contains a mitochondrial translocation signal from amino acids 368-463, suggesting its transport into mitochondria. A Molybdenum cofactor biosynthesis protein C region is found towards the C-terminus, from amino acids 414-636, and a disordered region is present between amino acids 456-480.
Key variants
Variants in the MOCS1 gene can alter the protein's structure or reduce its functional capacity, leading to impaired molybdenum cofactor biosynthesis. These genetic changes can range from single nucleotide substitutions to larger deletions or insertions, and their impact on protein function determines the severity of the associated condition. Carriers of certain MOCS1 variants typically do not experience symptoms themselves but can pass the variant on to their children.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1102+2T>C | - | Pathogenic/Likely pathogenic | ★★☆☆ | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A |
c.1150+1G>T | G297V, G384V | Pathogenic/Likely pathogenic | ★★☆☆ | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A |
c.1275del | p.Gly426fs | Pathogenic/Likely pathogenic | ★★☆☆ | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A |
c.142C>T | p.Gln48Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A |
c.271del | p.Glu91fs | Pathogenic | ★★☆☆ | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A |
c.291del | p.Ala99fs | Pathogenic | ★★☆☆ | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A |
c.306_309dup | p.Thr104fs | Pathogenic/Likely pathogenic | ★★☆☆ | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A |
c.519del | p.Ser173fs | Pathogenic/Likely pathogenic | ★★☆☆ | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A |
c.664C>T | p.Arg222Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A |
c.721del | p.Leu241fs | Pathogenic/Likely pathogenic | ★★☆☆ | Sulfite oxidase deficiency due to molybdenum cofactor deficiency type A |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the MOCS1 gene are primarily associated with Molybdenum cofactor deficiency [PMID:11932204]. This is a severe, inherited metabolic disorder characterised by neurological symptoms that often manifest early in life. Affected individuals typically experience seizures and progressive brain dysfunction (encephalopathy), which can unfortunately be fatal in early childhood. The severity of the condition depends on the specific genetic variant and its impact on molybdenum cofactor production.
Inheritance pattern
Conditions caused by pathogenic MOCS1 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
The MOCS1 gene is included in several expert-curated panels within the NHS Genomic Medicine Service, indicating its clinical significance in the UK. It is present in DDG2P, the Early onset or syndromic epilepsy panel, Foetal anomalies (R21), Intellectual disability, Likely inborn error of metabolism (R98), and Undiagnosed metabolic disorders panels, all listed with a 'green' status. This signifies that there is strong evidence for MOCS1's association with these conditions and that variants in this gene are routinely assessed in relevant clinical contexts.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is molybdenum cofactor deficiency?
Molybdenum cofactor deficiency is a rare, inherited metabolic disorder caused by the body's inability to produce sufficient molybdenum cofactor. This leads to the accumulation of toxic substances and severe neurological problems, typically appearing in infancy.
How is MOCS1 related to molybdenum cofactor deficiency?
The MOCS1 gene provides instructions for essential proteins involved in the first steps of molybdenum cofactor synthesis. Pathogenic variants in MOCS1 disrupt this process, leading directly to the deficiency and its associated health issues.
What does 'autosomal recessive inheritance' mean for MOCS1?
Autosomal recessive inheritance means that a person must inherit two copies of a pathogenic MOCS1 variant, one from each parent, to develop molybdenum cofactor deficiency. Individuals with only one pathogenic variant are typically carriers and usually do not show symptoms.
References
- Mendel RR. The molybdenum cofactor. The Journal of biological chemistry. 2013. PMID: 23539623
- Leimkühler S, Charcosset M, Latour P. Ten novel mutations in the molybdenum cofactor genes MOCS1 and MOCS2 and in vitro characterization of a MOCS2 mutation that abolishes the binding ability of molybdopterin synthase. Human genetics. 2005. PMID: 16021469
- Reiss J, Johnson JL. Mutations in the molybdenum cofactor biosynthetic genes MOCS1, MOCS2, and GEPH. Human mutation. 2003. PMID: 12754701